- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Cingulate Appoints Zhanpeng Jiang to Board of Directors
Jiang granted 15,000 stock options and added to key board committees
Apr. 2, 2026 at 8:05pm
Got story updates? Submit your updates here. ›
Cingulate's appointment of Zhanpeng Jiang to its board of directors recognizes his industry experience and potential to contribute to the company's strategic direction.Kansas City TodayCingulate Inc., a biopharmaceutical company, has appointed Zhanpeng 'Frederick' Jiang as an independent Class I director on its Board of Directors. Jiang was also added to the company's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
Why it matters
Jiang's appointment to Cingulate's board brings additional expertise and experience that could benefit the company as it continues to develop its pipeline of pharmaceutical products. His addition to key board committees also indicates that Cingulate values his input on important decisions.
The details
As part of his appointment, Jiang was granted an option to purchase 15,000 shares of Cingulate's common stock. The option will vest over a one-year period in two equal installments. Jiang will also receive annual cash retainers for his board and committee service, in line with Cingulate's Non-Employee Director Compensation Program.
- Jiang was appointed to the Cingulate board on March 27, 2026, following stockholder approval.
The players
Zhanpeng 'Frederick' Jiang
An independent Class I director on the Cingulate Inc. Board of Directors, and a member of the company's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
Cingulate Inc.
A biopharmaceutical company developing a pipeline of pharmaceutical products.
The takeaway
Cingulate's appointment of Zhanpeng Jiang to its board demonstrates the company's commitment to strengthening its leadership and governance as it continues to advance its drug development efforts.
